Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 6, 2008, Pages 616-619

  Mohanty, Nayan Kumar ^a   Nayak, Rajiba L ^a   Vasudeva, Pawan ^a   Arora, Rajender P ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

BCG; Gemcitabine; Nonresponder

Indexed keywords

BCG VACCINE; GEMCEL; GEMCITABINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CYSTITIS; CYSTOSCOPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; MALE; MUSCLE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; URINARY FREQUENCY;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 55249106977     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.10.016     Document Type: Article

References (19)

1. Oosterlinck W., Lobel B., Jakse G., et al. Guidelines on bladder cancer. European Association of Urology (EAU) Working Group on Oncological Urology. Eur Urol 41 (2002) 105-112
2. Huncharek M., and Kupelnick B. Impact of Intravesical chemotherapy vs. BCG immunotherapy on recurrences of superficial transitional cell carcinoma of the bladder: Meta analytic reevaluation. Am J Clin Oncol 26 (2003) 402-407
3. Bohle A., Jocham D., and Bock P.R. Intravesical BCG vs. mitomycin-C for superficial bladder cancer, a formal meta-analysis of comparative studies on recurrences and toxicity. J Urol 169 (2003) 90-95
4. Peyromaure M., Guerin F., Amsellem Q.D., et al. Intravesical bacillus Calmette-Guerin therapy for Stage T1 Grade III TCC of the bladder: Recurrences, progression, and survival in a study of 57 patients. J Urol 169 (2003) 2110-2112
5. Christopher P. Evans. Intravesical gemcitabine shows promise in intermediate risk superficial bladder cancer. Eur Urol 46 (2004) 339-343
6. Herr H.W., and Dalbagni G. Defining Bacillus Calmette Guerin refractory superficial bladder tumors. J Urol 169 (2003) 1706-1708
7. Konety B.R., and Williams R.D. Superficial Transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU Int 94 (2004) 18-21
8. Lamm D.L. Intravesical therapy for superficial bladder cancer: slow but steady progress. J Clin Oncol 21 (2003) 4259-4260
9. Stadler W.H., Kuzel T., Roth B., et al. Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15 (1997) 3394-3398
10. Lorusco V., Pollera C.F., Antimi M., et al. A Phase II study of gemcitabine in patients with TCC of the urinary tract previously treated with platinum. Italian Cooperative Group in Bladder Cancer. Eur J Cancer 34 (1998) 1208-1212
11. Kilani R.T., Tamini Y., Karmali S., et al. Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer drugs 13 (2002) 557-566
12. O'Donnell M.A., Evanoff D., and Luo Y. Studies on gemcitabine as an intravesical agent for superficial bladder cancer. J Urol 4 Suppl (2003) 508
13. Gontero P., Casetta G., Maso G., et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate risk superficial bladder cancer (SBC). Eur Urol 46 (2004) 339-343
14. Dalbagni G., Mazumdar M., Russo P., et al. Phase II trial of intravesical gemcitabine in BCG refractory transitional cell carcinoma of the bladder. J Urol 171 (2004) A274
15. Bartoletti R., Gacci M., Cai T., et al. Adjuvant intravesical gemcitabine in intermediate or high risk transitional cell carcinoma (TCC) of the bladder. JCO 22 14S (2004) 4601 [Abstract].
16. Bouzid K., Ferhat A., Bounedjar A., et al. Intravesical gemcitabine single agent as adjuvant chemotherapy in superficial TCC of the bladder. JCO 22 Suppl (2004) A4601
17. De Berardinis E., Antonini G., Autran-Gomes A.M., et al. Intravesical administration of gemcitabine in superficial bladder cancer-a Phase I study with pharmaco dynamic evaluation. Phase-II study with chemo resection of the marker lesion. J Urol 171 (2004) A275
18. Serretta V., Pavone C., Galuffo A., et al. A Phase I-II study on intravesical gemcitabine in superficial bladder papillary tumors. J Urol 171 (2004) A272
19. Laufer M., Ramalingam S., Schoenbarg M.P., et al. Intravesical gemcitabine therapy for superficial TCC of the bladder-a Phase I and pharmacokinetic study. J Clin Oncol 21 (2003) 4 697-703.